Novartis discrimination suit heads for trial

A class-action lawsuit alleging that Novartis discriminated against thousands of female sales representatives is expected to go to trial next year after a federal court judge denied the drugmaker's motion for a partial summary judgement on Tuesday. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.